Aurinia Pharmaceuticals Inc. 8-K

What Happened
Aurinia Pharmaceuticals Inc. announced its financial results for the three and twelve months ended December 31, 2025 via a press release dated February 26, 2026. The company furnished the release as Exhibit 99.1 to a Form 8‑K (Item 2.02) that reports its results of operations and financial condition; the filing was signed by Chief Financial Officer Joseph Miller.

Key Details

• Filing date: February 26, 2026 (Form 8‑K) — press release attached as Exhibit 99.1.
• Reporting periods: three months and twelve months ended December 31, 2025.
• Item disclosed: 2.02 (Results of Operations and Financial Condition); exhibit listed under Item 9.01 (Exhibits).
• The Form 8‑K furnishes the press release (information disclosed is furnished rather than filed).

Why It Matters
This 8‑K signals Aurinia’s public update on quarterly and full‑year 2025 earnings and operating results. Retail investors should read the attached press release for the actual earnings, revenue, cash‑flow, and any commentary on business progress or guidance, since the 8‑K itself references that release rather than embedding detailed financial tables. No executive changes, mergers, or other corporate events were reported in this filing.